9月3日上午
Advanced NSCLC: How should we integrate new facts on duration of therapy in the treatment algorithm of 2011
(如何选择晚期非小细胞肺癌治疗的持续时间)
Contemporary perspecive on Advanced NSCLC-A Shifting Paradigm in the First Line Therapy
(晚期非小细胞肺癌目前治疗策略：一线治疗模式的变迁)
Malignant pleural mesothelioma: Standards and new developments in medical treatment
(恶性胸膜间皮瘤的标准治疗及治疗新进展)
Second-Line therapy in advanced NSCLC: How to maximize efficacy
(晚期非小细胞肺癌二线治疗最佳策略)
Conflict-management within clinical and administrative stakeholders in medical structures
(医疗机构中临床和行政人员的风险和冲突管理)
Lung Cancer: Are three doses of stereotactic ablative body radiotherapy (SABR) more effective than three doses of conventional radiotherapy？
(肺癌: 三个剂量的立体定向放疗是否比同剂量的常规放疗更有效？)
Surgery Progess in Lung Cancer
(肺癌手术治疗新进展)
How to detect EGFR mutations: Consensus in China
(如何检测EGFR突变: 中国共识)
Treatment for elderly advanced NSCLC
(老年晚期非小细胞肺癌的治疗)
编辑: belinda_1231 作者:丁香园通讯员
以下网友留言只代表网友个人观点，不代表网站观点
